Patient Experience RatingPatient Experience Star Ratings and Comments
Industry Relationships
About Me
Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine. Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. He joined Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn's & Colitis Center at Massachusetts General Hospital in Boston, where he also served as the hospital's Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School.
A longtime advocate for the continued translational research in Crohn's disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. He was among the first to report the efficacy of infliximab-a drug used to treat autoimmune diseases-in ulcerative colitis, a result later confirmed in large, multi-center randomized controlled trials. Dr. Sands was also principal investigator for the landmark ACCENT II study, an international project that demonstrated the efficacy of the anti-tumor necrosis factor antibody infliximab as a long-term treatment for fistulizing Crohn's disease.
Dr. Sands' research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD in Rhode Island, a project that is funded by the Centers for Disease Control and Prevention.,
A leader in several major professional organizations, Dr. Sands has served as the chair of the Clinical Research Alliance of the Crohn's Foundation of America, Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA), and chair of the International Organization for the Study of IBD. He is an AGA Fellow (AGAF) and a fellow of the American College of Gastroenterology (FACG). In 2006 he was named Humanitarian of the Year by the New England Chapter of the Crohn's and Colitis Foundation of America, and the Massachusetts General Physician Organization honored him for "Excellence in Action" in recognition of his distinguished patient care.
His work has appeared in several leading peer-reviewed journals, including the New England Journal of Medicine, Gastroenterology and Gut. Dr. Sands is also a reviewer for many prominent publications, including the New England Journal of Medicine. Dr. Sands served as an Associate Editor for the field's leading journal, Gastroenterology, from 2011 to 2016.
Dr. Sands received his medical degree at Boston University School of Medicinein Massachusetts and completed a residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. He then completed clinical and research fellowships at the Massachusetts General Hospital. In 2001 Dr. Sands also earned a Master of Science in Epidemiology at Harvard School of Public Health.
Language
English
Position
PROFESSOR | Medicine, Gastroenterology
Hospital Affiliations
Mount Sinai Beth Israel
Mount Sinai Morningside
The Mount Sinai Hospital
Mount Sinai West
Show More
About Me
Bruce Sands, MD, MS is the Dr. Burrill B. Crohn Professor of Medicine. Dr. Sands is an expert in the management of inflammatory bowel diseases (IBD) and has earned an international reputation for his care of patients with complex and refractory disease. He joined Mount Sinai in 2010 as Chief of the Dr. Henry D. Janowitz Division of Gastroenterology. Prior to joining Mount Sinai, Dr. Sands was Medical Co-Director of the Crohn's & Colitis Center at Massachusetts General Hospital in Boston, where he also served as the hospital's Acting Chief of the Gastrointestinal Unit as well as Associate Professor of Medicine at Harvard Medical School.
A longtime advocate for the continued translational research in Crohn's disease and ulcerative colitis, Dr. Sands is widely recognized for his innovative treatment of IBD and for his clinical investigations of new therapeutics. He was among the first to report the efficacy of infliximab-a drug used to treat autoimmune diseases-in ulcerative colitis, a result later confirmed in large, multi-center randomized controlled trials. Dr. Sands was also principal investigator for the landmark ACCENT II study, an international project that demonstrated the efficacy of the anti-tumor necrosis factor antibody infliximab as a long-term treatment for fistulizing Crohn's disease.
Dr. Sands' research also explores IBD epidemiology and includes the creation of a population-based cohort of IBD in Rhode Island, a project that is funded by the Centers for Disease Control and Prevention.,
A leader in several major professional organizations, Dr. Sands has served as the chair of the Clinical Research Alliance of the Crohn's Foundation of America, Chair of the Immunology, Microbiology and Inflammatory Bowel Disease Section of the American Gastroenterological Association (AGA), and chair of the International Organization for the Study of IBD. He is an AGA Fellow (AGAF) and a fellow of the American College of Gastroenterology (FACG). In 2006 he was named Humanitarian of the Year by the New England Chapter of the Crohn's and Colitis Foundation of America, and the Massachusetts General Physician Organization honored him for "Excellence in Action" in recognition of his distinguished patient care.
His work has appeared in several leading peer-reviewed journals, including the New England Journal of Medicine, Gastroenterology and Gut. Dr. Sands is also a reviewer for many prominent publications, including the New England Journal of Medicine. Dr. Sands served as an Associate Editor for the field's leading journal, Gastroenterology, from 2011 to 2016.
Dr. Sands received his medical degree at Boston University School of Medicinein Massachusetts and completed a residency in internal medicine at the Hospital of the University of Pennsylvania in Philadelphia. He then completed clinical and research fellowships at the Massachusetts General Hospital. In 2001 Dr. Sands also earned a Master of Science in Epidemiology at Harvard School of Public Health.
Dr. Sands' research as a clinical investigator focuses on extending basic pathogenetic observations in the inflammatory bowel diseases--Crohn's disease and ulcerative colitis--to translational research and clinical trials. I have been an active investigator in clinical trials of novel agents directed at specific pathophysiologic targets in IBD in all phases of study. His earliest clinical trial work was with infliximab, a chimeric monoclonal anti-tumor necrosis factor antibody that has revolutionized the treatment of Crohn's disease. Dr. Sands was among the first to report on the efficacy of infliximab in ulcerative colitis, later borne out in large randomized controlled trials. Dr. Sands was also overall principal investigator for a large randomized controlled trial of infliximab in fistulizing Crohn's disease, the largest such study to date. In addistion to his work in clinical trials, Dr. Sands's research has included extensive work in observational studies in IBD, including outcomes research and epidemiologic studies. Most recently, he is the principal investigator of OSCCAR, the Ocean State Crohn's & Colitis Area Registry, a novel, prospective, population-based inception cohort of inflammatory bowel disease based in the state of Rhode Island. The goals of this study are to 1) develope robust predictive models for outcomes in IBD, and 2) to elucidate the role of environmental risk factors in the onset of IBD.
Accepted insurance may vary by the doctor’s office location. Please contact the office directly to obtain the most up-to-date insurance information.
Patients with Cigna Medicare Advantage or Humana Medicare Advantage insurance: Please read this important message before booking to find out if out-of-network costs may apply to your next visit.
Feinstein IBD Clinical Center17 East 102nd Street, 5th Floor, New York, NY, 10029
1199 SEIU
AETNA - Commercial
AETNA - Medicare
CIGNA Healthcare
Centivo
Elderplan
EmblemHealth - GHI-PPO
EmblemHealth - HIP
EmblemHealth - HIP-Medicare
Empire Blue Cross Blue Shield - Commercial/Exchange
Empire Blue Cross Blue Shield - Medicare
Horizon NJ
Magnacare-Health Care
Medicare - NJ
Medicare - NY
Multiplan PHCS
Oscar
Oxford - Freedom and Liberty
Partners Health Plan
United Health Care - Commercial
United Health Care - Empire Plan
United Health Care - Oxford Care
United Health Care - Top Tier
VNSNY Choice Medicare
VillageCareMax
WellCare Health Plan
Feinstein IBD Clinical Center17 East 102nd Street, 5th Floor, New York, NY, 10029
1199 SEIU
AETNA - Commercial
AETNA - Medicare
CIGNA Healthcare
Centivo
Elderplan
EmblemHealth - GHI-PPO
EmblemHealth - HIP
EmblemHealth - HIP-Medicare
Empire Blue Cross Blue Shield - Commercial/Exchange
Empire Blue Cross Blue Shield - Medicare
Horizon NJ
Magnacare-Health Care
Medicare - NJ
Medicare - NY
Multiplan PHCS
Oscar
Oxford - Freedom and Liberty
Partners Health Plan
United Health Care - Commercial
United Health Care - Empire Plan
United Health Care - Oxford Care
United Health Care - Top Tier
VNSNY Choice Medicare
VillageCareMax
WellCare Health Plan
1199 SEIU
AETNA - Commercial
AETNA - Medicare
CIGNA Healthcare
Centivo
Elderplan
EmblemHealth - GHI-PPO
EmblemHealth - HIP
EmblemHealth - HIP-Medicare
Empire Blue Cross Blue Shield - Commercial/Exchange
Show More
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
The Patient Experience Star Rating reflects our patients’ perception of how well their Mount Sinai provider communicated with them during an office visit. The Star Rating is based on patient responses to three questions on a patient experience survey, a standardized questionnaire sent to verified patients and distributed by a third party vendor, Press Ganey. Responses are measured on a scale of 1 to 5, with 5 being the best score.
Care Provider’s Explanation
5 out of 5
Care Provider’s Concern
5 out of 5
Likelihood to Recommend Care Provider
4.9 out of 5
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Sands during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Tr1X, Inc.
Fzata
Boehringer Ingelheim Corporation
Target RWE
Equilium, Inc.
Mitsubishi Tanabe Pharma Corportation
Teva Branded Pharmaceutical Products R&D, Inc.
Eli Lilly and Company
Quotient Therapeutics
Ono Pharmaceuticals
Disc Medicine, Inc.
Palisade Bio, Inc.
Adiso Therapeutics USA
Alimentiv
Rasayana Therapeutics
AstraZeneca
Takeda Development Center Americas, Inc.
Amgen Inc.
Galapagos
Bristol-Myers Squibb
Vividion Therapeutics
Janssen Pharmaceutica NV
Morphic Therapeutic
Odyssey Therapeutics
Numab Therapeutics
Genentech, Inc.
Glaxosmithkline
WebMD
Biora Therapeutics
MJH Healthcare Holdings
Slate Bio
Gilead Sciences
Mobius Care
Ferring Pharmaceuticals
Vindico Medical Education
Vedanta Biosciences
Celltrion
Agomab Therapeutics
Integritas Communications, LLC
FirstThought
Materia Prima
Celltrion USA
Merck Sharp & Dohme Corp
AnaptysBio, Inc
techspert.io
Abivax
Nimbus Discovery
Pfizer
Imhotex
Sorriso Therapeutics
AbbVie Inc.
MRM Health NV
EcoR1 Capital
Q32 Bio Inc.
Spyre Therapeutics
Recludix Pharma
Janssen Research & Development
Microbiotica Limited
Trex Bio
Nexus Therapeutics
Sanofi US Services Inc.
Ignite Biomedical
Ventyx Biosciences
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
Ventyx Biosciences
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Show More
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Below are financial relationships with industry reported by Dr. Sands during 2024 and/or 2025. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting or Other Professional Services Examples include, but are not limited to, committee participation, data safety monitoring board (DSMB) membership
Tr1X, Inc.
Fzata
Boehringer Ingelheim Corporation
Target RWE
Equilium, Inc.
Mitsubishi Tanabe Pharma Corportation
Teva Branded Pharmaceutical Products R&D, Inc.
Eli Lilly and Company
Quotient Therapeutics
Ono Pharmaceuticals
Disc Medicine, Inc.
Palisade Bio, Inc.
Adiso Therapeutics USA
Alimentiv
Rasayana Therapeutics
AstraZeneca
Takeda Development Center Americas, Inc.
Amgen Inc.
Galapagos
Bristol-Myers Squibb
Vividion Therapeutics
Janssen Pharmaceutica NV
Morphic Therapeutic
Odyssey Therapeutics
Numab Therapeutics
Genentech, Inc.
Glaxosmithkline
WebMD
Biora Therapeutics
MJH Healthcare Holdings
Slate Bio
Gilead Sciences
Mobius Care
Ferring Pharmaceuticals
Vindico Medical Education
Vedanta Biosciences
Celltrion
Agomab Therapeutics
Integritas Communications, LLC
FirstThought
Materia Prima
Celltrion USA
Merck Sharp & Dohme Corp
AnaptysBio, Inc
techspert.io
Abivax
Nimbus Discovery
Pfizer
Imhotex
Sorriso Therapeutics
AbbVie Inc.
MRM Health NV
EcoR1 Capital
Q32 Bio Inc.
Spyre Therapeutics
Recludix Pharma
Janssen Research & Development
Microbiotica Limited
Trex Bio
Nexus Therapeutics
Sanofi US Services Inc.
Ignite Biomedical
Ventyx Biosciences
Equity (Stock or stock options valued at greater than 5% ownership of a publicly traded company or equity of any value in a privately held company)
Ventyx Biosciences
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.